Featured News
Don’t Take Risks with Your Viral Vector Tech Transfer
Flexible viral vector tech transfer to facilitate therapeutic program continuity
Offering stability in times of change, our viral vector contract development and manufacturing organization (CDMO) team is well versed in offering advanced therapy developers both expertise and flexibility as they transfer their program in to our Maryland-based viral vector center of excellence.
With established processes, robust production platforms, and premium analytical capabilities, all developed over decades spent at the forefront of cell and gene therapy manufacturing, our methodical tech transfer framework lets you choose the technology you want to transfer (and when) to reduce the need for bridging or comparability studies.
Plug and Play: Seamless Viral Vector Tech Transfer
With the goal to facilitate project continuity and de-risk supply chains, the viral vector tech transfer framework can be utilized at any phase of development.
- Expertise and flexibility
- “Plug and Play” solution
- Unmatched experience
- Dedicated CDMO facility
- Comprehensive capabilities
Whether you're in Phase 1, pivotal, or ready for commercial manufacturing, our “plug and play” approach can be tailored to suit your needs; our experts can help you choose between either a Modular approach if your process isn’t fully developed or changes are needed, or a Fast Track approach if your process is more robust, facilitating tech transfer in as little as nine months.
Find Out More from BIO 2024
Charles River presented its viral vector tech transfer framework at the 2024 BIO International Convention in San Diego. You can watch Ramin Baghirzade, PhD, MBA, Senior Director, Global Head Commercial – Gene Therapy CDMO Services, as he explores Seamless Viral Vector Tech Transfer at Any Phase: Offering Stability in Times of Change.
Dr. Baghirzade commented in a press release announcing the offering: "Viral vector manufacturing and tech transfer is complex, requiring precision and accuracy to avoid costly and time-consuming program delays. Meticulously built to provide a seamless tech transfer at any phase, the viral vector tech transfer program provides stability in times of change.”
How Secure is your Viral Vector Supply?
A hot topic at BIO 2024, join Ramin Baghirzade as he explores considerations to stabilize your gene therapy program.
Watch On Demand
For more information on our plasmid DNA and comprehensive cell and gene therapy development and manufacturing services, please visit: Cell and Gene Therapy CDMO Solutions.